Abstract Library

#3050 Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis

Introduction: Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clift A

Authors: Clift A, Frilling A, Braat A, Alsafi A, Wasan H,

Keywords: liver, metastases, radioembolization, yttrium, selective internal radiation therapy,

#2023 International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors

Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Braat A

Authors: Braat A, Kappadath C, Ahmadzadehfar H, Stothers C, Deroose C,

Keywords: PRRT, Radioembolization, neuroendocrine tumors, metastasis, radionuclide treatments,

#2013 Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yittrium-90 PET Scan

Introduction: 90Y is commonly used in PRRT for NET. It has no gamma photon in its emission that significantly limits post-therapy imaging and dosimetry. Other than Bremsstrahlung imaging which bears hereditary drawbacks of poor resolution, PET scan has been used for post-PRRT imaging. However, in daily clinical practice, due to extremely low abundance of positron emission per decay and patient’s intolerability of prolonged scan time, it is very difficult to obtain a scan with decent quality.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Yan S

Authors: Yan S, Lim G,

Keywords: PRRT, PET scan, Yttrium 90, neuroendocrine tumor,

#1720 Yttrium90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marques B

Authors: Marques B, Martins R, Gonçalves B, Sousa M, Violante L,

Keywords: neuroendocrine, yttrium radioisotopes,

#1717 Yttrium-90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marques B

Authors: Marques B, Martins R, Gonçalves B, Sousa M, Violante L,

Keywords: neuroendocrine, yttrium radioisotopes,